From Big Pharma to Snapdragon episode artwork

EPISODE · Mar 14, 2025 · 52 MIN

From Big Pharma to Snapdragon

from Molecule to Market: Inside the outsourcing space · host Raman Sehgal

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Matthew Bio, CSO, Cambrex & President, Snapdragon Chemistry Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Matt, covering: The frustrating experience of not having ownership or being hands-on at big pharma middle management Recounting the early days of Snapdragon Chemistry and being in the right place at the right time to harness continuous process manufacturing Getting out of the way of your talented people to let them explore and shine The story behind how a proposed acquisition by Asymchem was blocked by the Treasury’s Committee on Foreign Investment in the United States (CFIUS)... Deciding to choose and stay at Cambrex post-acquisition, and having the freedom to use Snapdragon as a catalyst for growth Matt began his career in chemistry more than 30 years ago developing continuous processes for the manufacture and purification of acrylates at the former Rohm & Haas company. Matthew then moved to Columbia University and earned a PhD in Chemistry. Upon graduating, Matthew returned to industry as a process development chemist at Merck Research Laboratories.  In 2006, Matthew moved to Amgen where he worked on the development of both batch and continuous manufacturing solutions for synthetic drug substances. He also worked on the development of new manufacturing technologies for synthetic – biologic hybrid molecules. In 2015, Matthew was a founding member Snapdragon Chemistry, Inc., a contract development firm specialized in continuous manufacturing technology. He is author or inventor on more than 30 peer-reviewed publications and patents, and numerous regulatory filings. Matthew is driven by a passion for the development of new chemical technologies. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.  

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Matthew Bio, CSO, Cambrex & President, Snapdragon Chemistry Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Matt, covering: The frustrating experience of not having ownership or being hands-on at big pharma middle management Recounting the early days of Snapdragon Chemistry and being in the right place at the right time to harness continuous process manufacturing Getting out of the way of your talented people to let them explore and shine The story behind how a proposed acquisition by Asymchem was blocked by the Treasury’s Committee on Foreign Investment in the United States (CFIUS)... Deciding to choose and stay at Cambrex post-acquisition, and having the freedom to use Snapdragon as a catalyst for growth Matt began his career in chemistry more than 30 years ago developing continuous processes for the manufacture and purification of acrylates at the former Rohm & Haas company. Matthew then moved to Columbia University and earned a PhD in Chemistry. Upon graduating, Matthew returned to industry as a process development chemist at Merck Research Laboratories.  In 2006, Matthew moved to Amgen where he worked on the development of both batch and continuous manufacturing solutions for synthetic drug substances. He also worked on the development of new manufacturing technologies for synthetic – biologic hybrid molecules. In 2015, Matthew was a founding member Snapdragon Chemistry, Inc., a contract development firm specialized in continuous manufacturing technology. He is author or inventor on more than 30 peer-reviewed publications and patents, and numerous regulatory filings. Matthew is driven by a passion for the development of new chemical technologies. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

NOW PLAYING

From Big Pharma to Snapdragon

0:00 52:32

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of Molecule to Market: Inside the outsourcing space?

This episode is 52 minutes long.

When was this Molecule to Market: Inside the outsourcing space episode published?

This episode was published on March 14, 2025.

What is this episode about?

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Matthew Bio, CSO, Cambrex & President, Snapdragon Chemistry Your host, Raman Sehgal, discusses the pharmaceutical and...

Can I download this Molecule to Market: Inside the outsourcing space episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!